Global Star Acquisition Inc Ordinary Shares - Class A Azioni (OTC: GLST)

Ultime notizie per Global Star Acquisition Inc Ordinary Shares - Class A (OTC:GLST) Azioni

Global Star Acquisition Inc Ordinary Shares - Class A

GLOBAL STAR ACQUISITION INC RT

Global Star Acquisition Inc Units (1 Ord Class A, 1 War & 1 Right)

Global Star Acquisition Inc Warrants(15/07/2028)

Wells Fargo analyst Lawrence Biegelsen maintains Becton Dickinson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) with a Equal-Weight and raises the price target from $172 to $184.

News

Price Target

Analyst Ratings

Wells Fargo Maintains Equal-Weight on Becton Dickinson, Raises Price Target to $184

Cantor Fitzgerald analyst Yi Fu Lee maintains Nerdy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRDY#NYSE">NRDY</a>) with a Neutral and lowers the price target from $1.75 to $1.5.

NRDY

Cantor Fitzgerald Maintains Neutral on Nerdy, Lowers Price Target to $1.5

Wells Fargo analyst Lawrence Biegelsen maintains Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with a Overweight and raises the price target from $330 to $350.

PODD

Wells Fargo Maintains Overweight on Insulet, Raises Price Target to $350

Cantor Fitzgerald analyst Li Watsek maintains Ascendis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) with a Overweight and raises the price target from $200 to $203.

ASND

Cantor Fitzgerald Maintains Overweight on Ascendis Pharma, Raises Price Target to $203

Wells Fargo analyst Stan Berenshteyn maintains Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) with a Equal-Weight and raises the price target from $62 to $65.

DOCS

Wells Fargo Maintains Equal-Weight on Doximity, Raises Price Target to $65

Sonida Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDA#NYSE">SNDA</a>) will release its quarterly earnings report on Monday, 2025-08-11. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Sonida Senior Living to report an earnings per share (EPS) of $-0.78.
Sonida Senior Living bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
The company's EPS beat by $0.18 in the last quarter, leading to a 0.44% drop in the share price on the following day.
Here's a look at Sonida Senior Living's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.95</td>
<td>-0.71</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.77</td>
<td>-0.38</td>
<td>-0.98</td>
<td>-0.86</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.0%</td>
<td>-2.0%</td>
<td>0.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<h3>Stock Performance</h3>
Shares of Sonida Senior Living were trading at $24.27 as of August 07. Over the last 52-week period, shares are down 15.86%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<h3>Analyst Opinions on Sonida Senior Living</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Sonida Senior Living.
Analysts have given Sonida Senior Living a total of 1 ratings, with the consensus rating being Neutral. The average one-year price target is $26.0, indicating a potential 7.13% upside.
<h3>Peer Ratings Comparison</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Oncology Institute, Joint and US Physical Therapy, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Oncology Institute, with an average 1-year price target of $6.0, suggesting a potential 75.28% downside.</li>
<li>Analysts currently favor an Buy trajectory for Joint, with an average 1-year price target of $18.0, suggesting a potential 25.83% downside.</li>
<li>Analysts currently favor an Outperform trajectory for US Physical Therapy, with an average 1-year price target of $100.5, suggesting a potential 314.09% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
The peer analysis summary offers a detailed examination of key metrics for Oncology Institute, Joint and US Physical Therapy, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sonida Senior Living</td>
<td>Neutral</td>
<td>36.31%</td>
<td>$80.32M</td>
<td>-21.35%</td>
</tr>
<tr>
<td>Oncology Institute</td>
<td>Buy</td>
<td>10.29%</td>
<td>$17.25M</td>
<td>-371.33%</td>
</tr>
<tr>
<td>Joint</td>
<td>Buy</td>
<td>7.33%</td>
<td>$10.11M</td>
<td>4.24%</td>
</tr>
<tr>
<td>US Physical Therapy</td>
<td>Outperform</td>
<td>18.06%</td>
<td>$31.07M</td>
<td>2.45%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Sonida Senior Living ranks at the bottom for Revenue Growth and Gross Profit, indicating lower performance in these areas compared to its peers. However, it has the highest Return on Equity among the group, showcasing strong profitability relative to its equity. The consensus rating for Sonida Senior Living is neutral, suggesting a mixed sentiment towards the company compared to its peers.
<h3>Get to Know Sonida Senior Living Better</h3>
Sonida Senior Living Inc is an owner operator of senior housing communities in the United States in terms of resident capacity. It provides senior living services to the elderly, including independent living, assisted living, Respite Care and Temporary Care Programs, Home Care Services, and memory care services. The company's objective is to provide value to residents by providing quality senior housing services at reasonable prices. The basic service of the company is comprised of meals, housekeeping, laundry, 24-hour staffing, transportation, social and recreational activities, and healthcare monitoring.
<h3>Key Indicators: Sonida Senior Living's Financial Health</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Sonida Senior Living's remarkable performance in 3 months is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 36.31%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Sonida Senior Living's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -15.16%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -21.35%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Sonida Senior Living's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -1.67%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 11.08, caution is advised due to increased financial risk.
<a href="https://www.benzinga.com/quote/SNDA/earnings">To track all earnings releases for Sonida Senior Living visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

SNDA

A Preview Of Sonida Senior Living's Earnings

Harrow (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) will release its quarterly earnings report on Monday, 2025-08-11. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Harrow to report an earnings per share (EPS) of $0.04.
Anticipation surrounds Harrow's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company missed EPS by $0.39, leading to a 3.43% increase in the share price the following trading session.
Here's a look at Harrow's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.01</td>
<td>0.13</td>
<td>-0.05</td>
<td>-0.07</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.38</td>
<td>0.40</td>
<td>-0.05</td>
<td>-0.06</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-6.0%</td>
<td>-17.0%</td>
<td>54.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1754665539_0.png" alt="eps graph" />
<h3>Harrow Share Price Analysis</h3>
Shares of Harrow were trading at $33.21 as of August 07. Over the last 52-week period, shares are down 5.7%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<h3>Analysts' Perspectives on Harrow</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Harrow.
Harrow has received a total of 2 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $68.0, the consensus suggests a potential 104.76% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Innoviva, Phibro Animal Health and Amphastar Pharma, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Innoviva, with an average 1-year price target of $33.0, suggesting a potential 0.63% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Phibro Animal Health, with an average 1-year price target of $30.5, suggesting a potential 8.16% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Amphastar Pharma, with an average 1-year price target of $27.5, suggesting a potential 17.19% downside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
Within the peer analysis summary, vital metrics for Innoviva, Phibro Animal Health and Amphastar Pharma are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Harrow</td>
<td>Buy</td>
<td>38.29%</td>
<td>$32.31M</td>
<td>-28.20%</td>
</tr>
<tr>
<td>Innoviva</td>
<td>Buy</td>
<td>0.39%</td>
<td>$89.69M</td>
<td>9.35%</td>
</tr>
<tr>
<td>Phibro Animal Health</td>
<td>Neutral</td>
<td>32.14%</td>
<td>$104.57M</td>
<td>8.14%</td>
</tr>
<tr>
<td>Amphastar Pharma</td>
<td>Neutral</td>
<td>-0.76%</td>
<td>$85.25M</td>
<td>3.41%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Harrow ranks highest in Revenue Growth among its peers. It has the lowest Gross Profit margin. Harrow has the lowest Return on Equity.
<h3>About Harrow</h3>
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
<h3>Financial Insights: Harrow</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Harrow showcased positive performance, achieving a revenue growth rate of 38.29% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -37.17%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Harrow's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -28.2%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Harrow's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -4.72%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 4.07, caution is advised due to increased financial risk.
<a href="https://www.benzinga.com/quote/HROW/earnings">To track all earnings releases for Harrow visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HROW

A Preview Of Harrow's Earnings

Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) with a Equal-Weight and lowers the price target from $3 to $2.

CABA

Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Lowers Price Target to $2

Repay Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPAY#NASDAQ">RPAY</a>) is gearing up to announce its quarterly earnings on Monday, 2025-08-11. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Repay Hldgs will report an earnings per share (EPS) of $0.17.
Repay Hldgs bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings History Snapshot</h3>
In the previous earnings release, the company missed EPS by $0.00, leading to a 2.23% drop in the share price the following trading session.
Here's a look at Repay Hldgs's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.22</td>
<td>0.25</td>
<td>0.22</td>
<td>0.22</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.22</td>
<td>0.24</td>
<td>0.23</td>
<td>0.22</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>-14.000000000000002%</td>
<td>-1.0%</td>
<td>-10.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1754665526_0.png" alt="eps graph" />
<h3>Market Performance of Repay Hldgs's Stock</h3>
Shares of Repay Hldgs were trading at $5.32 as of August 07. Over the last 52-week period, shares are down 33.85%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analysts' Take on Repay Hldgs</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Repay Hldgs.
Analysts have provided Repay Hldgs with 4 ratings, resulting in a consensus rating of Neutral. The average one-year price target stands at $4.62, suggesting a potential 13.16% downside.
<h3>Analyzing Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of PaySign, Cantaloupe and Flywire, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for PaySign, with an average 1-year price target of $8.33, suggesting a potential 56.58% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Cantaloupe, with an average 1-year price target of $14.0, suggesting a potential 163.16% upside.</li>
<li>Analysts currently favor an Buy trajectory for Flywire, with an average 1-year price target of $13.1, suggesting a potential 146.24% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
The peer analysis summary provides a snapshot of key metrics for PaySign, Cantaloupe and Flywire, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Repay Holdings</td>
<td>Neutral</td>
<td>-4.21%</td>
<td>$58.66M</td>
<td>-1.05%</td>
</tr>
<tr>
<td>PaySign</td>
<td>Buy</td>
<td>2.58%</td>
<td>$11.69M</td>
<td>3.41%</td>
</tr>
<tr>
<td>Cantaloupe</td>
<td>Outperform</td>
<td>11.09%</td>
<td>$31.36M</td>
<td>22.69%</td>
</tr>
<tr>
<td>Flywire</td>
<td>Buy</td>
<td>27.21%</td>
<td>$78.00M</td>
<td>-1.52%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Repay Holdings ranks at the bottom for Revenue Growth among its peers. It is also at the bottom for Gross Profit. However, it is in the middle for Return on Equity.
<h3>About Repay Hldgs</h3>
Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments.
<h3>Key Indicators: Repay Hldgs's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Challenges: Repay Hldgs's revenue growth over 3 months faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -4.21%. This indicates a decrease in top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Repay Hldgs's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -10.28%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Repay Hldgs's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -1.05%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Repay Hldgs's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.51%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Repay Hldgs's debt-to-equity ratio is below the industry average at 0.67, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/RPAY/earnings">To track all earnings releases for Repay Hldgs visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RPAY

A Look at Repay Hldgs's Upcoming Earnings Report

Cannae Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNNE#NYSE">CNNE</a>) will release its quarterly earnings report on Monday, 2025-08-11. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Cannae Holdings to report an earnings per share (EPS) of $-0.29.
The market awaits Cannae Holdings's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings Track Record</h3>
The company's EPS missed by $0.19 in the last quarter, leading to a 5.32% drop in the share price on the following day.
Here's a look at Cannae Holdings's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.40</td>
<td>-0.29</td>
<td>-0.22</td>
<td>-0.17</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.59</td>
<td>-0.74</td>
<td>-0.22</td>
<td>-2.49</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>-0.0%</td>
<td>-3.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1754665510_0.png" alt="eps graph" />
<h3>Cannae Holdings Share Price Analysis</h3>
Shares of Cannae Holdings were trading at $19.68 as of August 07. Over the last 52-week period, shares are up 9.44%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Insights on Cannae Holdings</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Cannae Holdings.
The consensus rating for Cannae Holdings is Outperform, derived from 2 analyst ratings. An average one-year price target of $24.0 implies a potential 21.95% upside.
<h3>Peer Ratings Comparison</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of and Cannae Holdings, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<h3>Summary of Peers Analysis</h3>
The peer analysis summary presents essential metrics for and Cannae Holdings, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cannae Holdings</td>
<td>Outperform</td>
<td>-6.78%</td>
<td>$-2M</td>
<td>-6.35%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Cannae Holdings ranks at the bottom among its peers in terms of revenue growth, with a negative growth rate of -6.78%. Its gross profit is reported at $-2M, indicating a challenging financial position compared to its peers. The return on equity for Cannae Holdings is -6.35%, reflecting a lower performance in generating profits from shareholders' equity. Overall, Cannae Holdings lags behind its peers in key financial metrics.
<h3>About Cannae Holdings</h3>
Cannae Holdings Inc is a holding company that manages and operates a group of companies and investments. The company's reportable segments are Restaurant Group, Dun &amp; Bradstreet, Alight, BKFC, Corporate and Other. Majority of the company's revenue is generated from its Restaurant Group segment which represents the operations of O'Charley's and Ninety Nine Restaurants.
<h3>Financial Milestones: Cannae Holdings's Journey</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: Cannae Holdings's revenue growth over 3 months faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -6.78%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Cannae Holdings's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -109.5%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -6.35%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Cannae Holdings's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -5.23%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.19.
<a href="https://www.benzinga.com/quote/CNNE/earnings">To track all earnings releases for Cannae Holdings visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CNNE

A Glimpse of Cannae Holdings's Earnings Potential

Hallador Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HNRG#NASDAQ">HNRG</a>) is set to give its latest quarterly earnings report on Monday, 2025-08-11. Here's what investors need to know before the announcement.
Analysts estimate that Hallador Energy will report an earnings per share (EPS) of $-0.15. 
The market awaits Hallador Energy's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.39, leading to a 21.4% increase in the share price on the subsequent day.
Here's a look at Hallador Energy's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.16</td>
<td>-0.13</td>
<td>-0.10</td>
<td>-0.08</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.23</td>
<td>0.07</td>
<td>0.04</td>
<td>-0.27</td>
</tr>
<tr>
<td>Price Change %</td>
<td>21.0%</td>
<td>4.0%</td>
<td>26.0%</td>
<td>-22.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1754665460_0.png" alt="eps graph" />
<h3>Performance of Hallador Energy Shares</h3>
Shares of Hallador Energy were trading at $19.97 as of August 07. Over the last 52-week period, shares are up 277.92%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Views on Hallador Energy</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Hallador Energy.
Hallador Energy has received a total of 1 ratings from analysts, with the consensus rating as Outperform. With an average one-year price target of $23.0, the consensus suggests a potential 15.17% upside.
<h3>Comparing Ratings with Peers</h3>
The below comparison of the analyst ratings and average 1-year price targets of AES and Vistra, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for AES, with an average 1-year price target of $13.5, suggesting a potential 32.4% downside.</li>
<li>Analysts currently favor an Buy trajectory for Vistra, with an average 1-year price target of $193.0, suggesting a potential 866.45% upside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
The peer analysis summary provides a snapshot of key metrics for AES and Vistra, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hallador Energy</td>
<td>Outperform</td>
<td>5.57%</td>
<td>$67.35M</td>
<td>9.09%</td>
</tr>
<tr>
<td>AES</td>
<td>Outperform</td>
<td>-2.96%</td>
<td>$453M</td>
<td>-3.07%</td>
</tr>
<tr>
<td>Vistra</td>
<td>Buy</td>
<td>28.78%</td>
<td>$793M</td>
<td>-11.65%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Hallador Energy ranks highest in Gross Profit among its peers. It is in the middle for Revenue Growth. The company's Return on Equity is the highest.
<h3>Get to Know Hallador Energy Better</h3>
Hallador Energy Co is a coal mining company with operations in Indiana, USA, and it is part of the electric power generation industry. The operations of the company are divided into two primary reportable segments, the Coal Operations and Electric Operations segments. The majority of revenue is earned from the Coal Operations segment.
<h3>Hallador Energy's Economic Impact: An Analysis</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Hallador Energy's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 5.57% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Utilities sector.
Net Margin: Hallador Energy's net margin is impressive, surpassing industry averages. With a net margin of 8.47%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 9.09%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Hallador Energy's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.71% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.3, Hallador Energy adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/HNRG/earnings">To track all earnings releases for Hallador Energy visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HNRG

Earnings Preview: Hallador Energy

Uber Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) and Dollar General Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) have launched a <a href="https://www.benzinga.com/pressreleases/25/08/b46995497/dollar-general-and-uber-eats-partner-to-deliver-household-essentials-nationwide" target="_blank" rel="noreferrer noopener">new partnership</a>, starting August 8, that will enable on-demand delivery from more than 14,000 Dollar General and pOpshelf locations across the U.S. via Uber Eats.
Customers can now order a wide range of low-cost groceries, household items, and trending merchandise through the Uber Eats app and receive them at their doorstep, either on-demand or at a scheduled time. The service is rolling out nationwide throughout August.
Tony Rogers, Dollar General&#8217;s Chief Marketing Officer, said the partnership delivers added convenience while aligning with the brand&#8217;s mission. &#8220;Our customers will enjoy even greater convenience through our Uber Eats partnership, accessing everything from food to essential household items, saving them valuable time and money,&#8221; he said.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/earnings/25/08/46958662/uber-may-sell-stake-to-fund-robotaxis-says-ceo-dara-khosrowshahi-as-teslas-own-self-driving-pilot-gains-ground" rel="noreferrer noopener">Uber May Sell Stake To Fund Robotaxis, Says CEO Dara Khosrowshahi As Tesla&#8217;s Own Self-Driving Pilot Gains Ground</a>
Hashim Amin, Head of Grocery &amp; Retail at Uber, highlighted the growing demand for flexibility in retail. &#8220;Retailers today are navigating a rapidly changing landscape, consumers expect convenience, speed, and accessibility like never before,&#8221; he said. &#8220;We&#8217;re proud to help extend Dollar General&#8217;s reach into the on-demand economy.&#8221;
To celebrate the rollout, Uber Eats is offering 40% off orders of $20 or more (up to $10) with promo code 40GENERAL. Uber One members will also benefit from free delivery and additional savings.
<h2 class="wp-block-heading">How It Works</h2>
Users can access the service by opening the Uber Eats app, selecting the &#8220;Grocery&#8221; or &#8220;Convenience&#8221; section, searching for Dollar General or pOpshelf, and placing an order with real-time tracking.
This collaboration underscores Uber&#8217;s efforts to grow its retail delivery footprint. Analysts have noted that Uber is <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/08/46969348/uber-q2-beat-well-positioned-to-drive-strong-growth-analysts-say" target="_blank" rel="noreferrer noopener">well-positioned to drive strong growth</a> following better-than-expected second-quarter results.
Investors may also monitor ETFs like Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) and SPDR S&amp;P Retail ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XRT#NYSE">XRT</a>).
Price Action: DG shares are trading higher by 1.83% to $117.75 and UBER is down 0.98% at $91.74 at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/node/46998045" target="_blank" rel="noreferrer noopener">Weak Guidance And Tariff Worries Send Under Armour Stock Tumbling</a></li>
</ul>
Photo by Pamela Brick via Shutterstock

Movers

UBER

Select Sector SPDR-Consumer Discretionary

Dollar General Joins Uber Eats In Nationwide Delivery Push

Orla Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ORLA#AMEX">ORLA</a>) is gearing up to announce its quarterly earnings on Monday, 2025-08-11. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Orla Mining will report an earnings per share (EPS) of $0.18.
Investors in Orla Mining are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
Here's a look at Orla Mining's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.12</td>
<td>0.07</td>
<td>0.06</td>
<td>0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>-2.0%</td>
<td>-10.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<h3>Performance of Orla Mining Shares</h3>
Shares of Orla Mining were trading at $10.36 as of August 07. Over the last 52-week period, shares are up 181.75%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/ORLA/earnings">To track all earnings releases for Orla Mining visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ORLA

Earnings Outlook For Orla Mining

WW International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>) is set to give its latest quarterly earnings report on Monday, 2025-08-11. Here's what investors need to know before the announcement.
Analysts estimate that WW International will report an earnings per share (EPS) of $0.12. 
Investors in WW International are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings Track Record</h3>
During the last quarter, the company reported an EPS missed by $0.10, leading to a 43.04% drop in the share price on the subsequent day.
Here's a look at WW International's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.37</td>
<td>-0.02</td>
<td>0.06</td>
<td>0.01</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.47</td>
<td>0.04</td>
<td>0.24</td>
<td>-0.13</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-43.0%</td>
<td>-20.0%</td>
<td>-0.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1754665444_0.png" alt="eps graph" />
<h3>Market Performance of WW International's Stock</h3>
Shares of WW International were trading at $38.03 as of August 07. Over the last 52-week period, shares are up 5027.0%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/WW/earnings">To track all earnings releases for WW International visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: WW International's Quarterly Earnings

The Federal Trade Commission (FTC) on Wednesday moved to block medical device supplier Edwards Lifesciences Corp.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) proposed acquisition of JenaValve Technology, Inc.
What Happened: "Edwards' attempt to buy the U.S. market for TAVR-AR devices would eliminate the head-to-head competition that has spurred innovation for lifesaving artificial heart valves," said Daniel Guarnera, Director of the FTC's Bureau of Competition.
The deal would limit patient access to lifesaving medical devices, the FTC argues.
So far, Edwards has agreed to <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39967649/edwards-lifesciences-stock-tumbles-highlights-slowdown-in-tavr-business" target="_blank" rel="noreferrer noopener">acquire both JenaValve</a> and JC Medical — the two companies competing to bring to market transcatheter aortic valve replacement devices. These devices treat a heart condition called aortic regurgitation (TAVR-AR devices).
Also Read: <a href="https://www.benzinga.com/markets/equities/25/08/46911067/edwards-lifesciences-stock-likely-to-see-sluggish-price-action-through-2027" target="_blank" rel="noreferrer noopener">Edwards Lifesciences Stock: Likely To See Sluggish Price Action Through 2027</a>
Why It Matters: Edwards closed its acquisition of JC Medical in July 2024. Its proposed $945 million acquisition of JenaValve would combine the only two companies with ongoing clinical trials in the U.S. for a TAVR-AR device.
The deal <a href="https://www.ftc.gov/news-events/news/press-releases/2025/08/ftc-challenges-anticompetitive-medical-device-deal" target="_blank" rel="noreferrer noopener">threatens</a> to reduce competition in the TAVR-AR market. This would likely result in reduced innovation, diminished product quality, and potentially increased prices for consumers, according to <a href="https://www.ftc.gov/system/files/ftc_gov/pdf/d9442_p3_complaint_public_redacted_0.pdf" target="_blank" rel="noreferrer noopener">the complaint</a>.
More than 8 million Americans suffer from aortic regurgitation. That&#8217;s when the heart's aortic valve does not close properly, causing blood to backflow into the heart.
Surgical valve replacement via open-heart surgery is the only U.S. Food and Drug Administration (FDA)- approved procedure to treat aortic regurgitation. TAVR-AR devices offer a less invasive way to treat the condition.
JenaValve aims to become the first company to bring a TAVR-AR device, called Trilogy, to the U.S. commercial market.
FDA approval or commercialization of any other TAVR-AR device in the U.S. by another company, aside from Edwards and JenaValve, is not expected for the foreseeable future.
Direct head-to-head competition between Edwards, through its now-subsidiary JC Medical, and JenaValve has driven the two companies to accelerate the development of their TAVR-AR devices, the FTC's complaint alleges.
Ultimately, patients will benefit if JenaValve and Edwards continue directly competing and complete their separate TAVR-AR device clinical trials, product improvements, and commercialization plans.
The competition concerns caused by Edwards' dual acquisition strategy are predicated on Edwards owning both JenaValve and JC Medical simultaneously. Still, Edwards has elected to attempt to buy JenaValve while retaining its ownership of JC Medical.
What&#8217;s Next: Edwards intends to continue to pursue regulatory approval of the acquisition and estimates a final determination by the end of the first quarter of 2026.
So far, Edwards has not been willing to divest JC Medical to resolve the competition concerns associated with the proposed JenaValve acquisition, according to the complaint.
The FTC voted to authorize a temporary restraining order, and a preliminary injunction was 3-0.
On Wednesday, Edwards <a href="https://www.edwards.com/newsroom/news/2025-08-06-edwards-lifesciences-comments-on-ftc-s-action-to-b" target="_blank" rel="noreferrer noopener">disagreed</a> with the FTC's decision. Acquiring JenaValve will accelerate the availability, adoption, and continued innovation for AR treatment, the company stated.
In light of FTC's action, Edwards is revising its full-year 2025 financial guidance. There is no impact on revenue guidance of $5.90 billion-$6.10 billion.
The company is increasing its adjusted earnings guidance for fiscal 2025 to the high-end of $2.45-$2.55 per share. That&#8217;s up from the <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46639989/edwards-lifesciences-lifts-2025-outlook-on-strong-first-half-performance" target="_blank" rel="noreferrer noopener">high-end of $2.40-$2.50</a>.
There will be minimal impact on the company's third-quarter adjusted EPS guidance.
In July, the company increased its underlying growth rate guidance for TAVR to 6% to 7%. Its sales guidance range for TAVR is $4.3 billion to $4.5 billion.
Price Action: EW stock is up 0.23% at $78.11 at the last check on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/08/46992346/ford-delays-plans-for-electric-pickup-van-to-2028-amid-affordable-ev-push-due-to-stiff-competition-from-china" target="_blank" rel="noreferrer noopener">Ford Delays Plans For Electric Pickup, Van to 2028 Amid Affordable EV Push Due To Stiff Competition From China</a></li>
</ul>
Image: Shutterstock

Large Cap

Health Care

General

FTC Sounds Alarm On Edwards' Attempt To Corner Heart Device Market

Archer Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) is gearing up to announce its quarterly earnings on Monday, 2025-08-11. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Archer Aviation will report an earnings per share (EPS) of $-0.20.
The announcement from Archer Aviation is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Past Earnings Performance</h3>
The company's EPS beat by $0.05 in the last quarter, leading to a 22.91% increase in the share price on the following day.
Here's a look at Archer Aviation's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.22</td>
<td>-0.26</td>
<td>-0.32</td>
<td>-0.33</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.17</td>
<td>-0.45</td>
<td>-0.29</td>
<td>-0.32</td>
</tr>
<tr>
<td>Price Change %</td>
<td>23.0%</td>
<td>12.0%</td>
<td>11.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1754665388_0.png" alt="eps graph" />
<h3>Market Performance of Archer Aviation's Stock</h3>
Shares of Archer Aviation were trading at $9.8 as of August 07. Over the last 52-week period, shares are up 170.85%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/ACHR/earnings">To track all earnings releases for Archer Aviation visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACHR

Archer Aviation Earnings Preview

Revealing a significant insider sell on August 7, Amy M Fernandez, SVP at Trex Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TREX#NYSE">TREX</a>), as per the latest SEC filing.
What Happened: Fernandez opted to sell 1,538 shares of Trex Co, according to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001069878/000112760225020209//Archives/edgar/data/1069878/000112760225020209/0001127602-25-020209-index.htm">U.S. Securities and Exchange Commission</a> on Thursday. The transaction's total worth stands at $98,711.
Trex Co shares are trading up 0.02% at $61.47 at the time of this writing on Friday morning.
<h3>Get to Know Trex Co Better</h3>
Trex Co Inc is a manufacturer of wooden alternative decking products. The company offers outdoor products in the decking, railing, porch, fencing, trim, steel deck framing, and outdoor lighting categories. Its products are sold under the Trex brand and manufactured in the United States. Further, the company licenses its Trex brand to third parties to manufacture and sell products under the Trex trademark. The distribution is focused on wholesale distributors and retail lumber dealers, which in turn sell Trex products to homeowners and contractors, with an emphasis on professional contractors, remodelers, and homebuilders. The company operates in one reportable segment i.e. Trex Residential.
<h3>Trex Co: Financial Performance Dissected</h3>
Revenue Growth: Trex Co's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2025, the company achieved a revenue growth rate of approximately 3.01%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Navigating Financial Profits:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 40.78%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Trex Co's EPS is below the industry average. The company faced challenges with a current EPS of 0.71. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: Trex Co's debt-to-equity ratio is below the industry average. With a ratio of 0.3, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Insights into Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: Trex Co's current Price to Earnings (P/E) ratio of 35.32 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 5.85 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): At 22.12, the company's EV/EBITDA ratio outperforms industry norms, reflecting positive market perception. This positioning indicates optimistic expectations for the company's future performance.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
Investors should view insider transactions as part of a multifaceted analysis and not rely solely on them for decision-making.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Transaction Codes To Focus On</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001069878">Check Out The Full List Of Trex Co's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

TREX

Trex Co SVP Sold $98K In Company Stock

WIIM

CAPR

Capricor Therapeutics shares are trading higher after the company announced a Type A meeting with the FDA for Deramiocel.

James C Freeders, SVP at Oshkosh (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>), reported an insider sell on August 7, according to a new SEC filing. 
What Happened: Freeders's decision to sell 12,125 shares of Oshkosh was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000775158/000106299325013815//Archives/edgar/data/775158/000106299325013815/0001062993-25-013815-index.htm">U.S. Securities and Exchange Commission</a> on Thursday. The total value of the sale is $1,656,956.
Tracking the Friday's morning session, Oshkosh shares are trading at $137.93, showing a up of 2.0%.
<h3>Discovering Oshkosh: A Closer Look</h3>
Oshkosh Corp is the top producer of access equipment, specialty vehicles, and military trucks. It serves diverse end markets, where it is typically the market share leader in North America, or, in the case of JLG aerial work platforms. The company had manufactured joint light tactical vehicles for the U.S. Department of Defense. The company reports in three segments: Access, Vocational and Defense. It derives maximum revenue from Access Segment.
<h3>Understanding the Numbers: Oshkosh's Finances</h3>
Revenue Growth: Oshkosh's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2025, the company experienced a revenue decline of approximately -4.03%. This indicates a decrease in the company's top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.
Exploring Profitability:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 19.2%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Oshkosh's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 3.17.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.34.
Assessing Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 13.58 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 0.85 is lower than the industry average, implying a discounted valuation for Oshkosh's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Oshkosh's EV/EBITDA ratio at 8.33 suggests potential undervaluation, falling below industry averages.
</li>
</ul>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Understanding the Significance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000775158">Check Out The Full List Of Oshkosh's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

James C Freeders Implements A Sell Strategy: Offloads $1.66M In Oshkosh Stock

A new SEC filing reveals that Rainer Gawlick, Director at Proto Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>), made a notable insider purchase on August 7,.
What Happened: Gawlick's recent move, as outlined in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001443669/000162828025038875//Archives/edgar/data/1443669/000162828025038875/0001628280-25-038875-index.htm">U.S. Securities and Exchange Commission</a> on Thursday, involves purchasing 1,715 shares of Proto Labs. The total transaction value is $75,104.
As of Friday morning, Proto Labs shares are up by 2.29%, currently priced at $47.35.
<h3>Get to Know Proto Labs Better</h3>
Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. Proto Labs uses injection molding, computer numerical control machining, and 3-D printing to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. Geographically, a majority of the company's revenue is derived from the United States and the rest from Europe.
<h3>Financial Insights: Proto Labs</h3>
Revenue Growth: Proto Labs displayed positive results in 3 months. As of 30 June, 2025, the company achieved a solid revenue growth rate of approximately 7.51%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 44.26%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Proto Labs's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 0.19.
</li>
</ul>
Debt Management: Proto Labs's debt-to-equity ratio is below the industry average. With a ratio of 0.0, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: Proto Labs's current Price to Earnings (P/E) ratio of 77.15 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 2.24 is above industry norms, reflecting an elevated valuation for Proto Labs's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Proto Labs's EV/EBITDA ratio stands at 17.54, surpassing industry benchmarks. This places the company in a position with a higher-than-average market valuation.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Uncovering the Importance of Insider Activity</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001443669">Check Out The Full List Of Proto Labs's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PRLB

Director At Proto Labs Buys $75K of Stock

Press Releases

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Global Star Acquisition Inc. - GLST

Global Star Acquisition Inc. and K Enter Holdings Inc. Announce the Form F-4 Registration Statement for Their Proposed Business Combination has been Declared Effective

Comments

Global Star Acquisition Inc Ordinary Shares - Class A

Notizie

Ultime notizie per Global Star Acquisition Inc Ordinary Shares - Class A (OTC:GLST) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO